Clinical Trial Update: 5-Azacytidine and Phenylbutyrate to Treat Severe Thalassemia [Phase 2]

View source ↗

Summary

This entry reports the completion of a Phase 2 clinical trial evaluating the combination of 5-azacytidine and phenylbutyrate for severe beta-thalassemia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Beta-thalassemia

Drugs mentioned

• Phenylbutyrate (phenylbutyrate)
• VIDAZA (AZACITIDINE)

Snippet

Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Conditions: Beta Thalassemia | Phase 2 | Status: COMPLETED